Synergistic effects mediated by inhibiting both the PI3K and the MAPK pathways have been reported for several types of cancers [28–30], and activation of the RAS/MAPK pathway may be associated with the synergistic effects of the PI3K/mTOR- and MEK-pathway inhibitors [31, 32]. Here, MAP2K7 is linked to cancer.